Other languages BioNTech SE Wiener Boerse

Equities

BNTX

US09075V1026

End-of-day quote Wiener Boerse Other stock markets 06:00:00 2024-06-16 pm EDT			5-day change	1st Jan Change
82.7 ^EUR	-5.27%		-5.27%	-13.39%

Jun. 18	US FDA Places Partial Clinical Hold on BioNTech's Cancer Drug Trial	MT
Jun. 17	Sector Update: Health Care Stocks Ease in Afternoon Trading	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

US FDA Places Partial Clinical Hold on BioNTech's Cancer Drug Trial	Jun. 18
Sector Update: Health Care Stocks Ease in Afternoon Trading	Jun. 17
Top Midday Stories: Nvidia Gets SCOTUS Review of Crypto Sales Lawsuit; Apple Supplier Develops Material for Solid-State Batteries; OpenAI Reportedly Launches Medical AI Tool; Walt Disney's 'Inside Out 2' Sets Biggest Opening of 2024; IQVentures to Acquire Aaron's	Jun. 17
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading	Jun. 17
BioNTech Says US FDA Placed Partial Clinical Hold on Cancer Drug Trial	Jun. 17
FDA stoppt Patientenaufnahme in Krebsstudie von Biontech-Partner	Jun. 17
US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug	Jun. 17
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading	Jun. 11
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading	Jun. 10
Indonesia ramps up fight against tuberculosis amid concerns on economic impact	Jun. 10
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading	Jun. 05
COVID shots for JN.1 variant neutralize newer strains, vaccine makers say	Jun. 05
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading	Jun. 03
GNW-Adhoc: Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem Lungenkarzinom	Jun. 01
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab	Jun. 01
Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem Lungenkarzinom	Jun. 01
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower	May. 31
BioNTech, CEPI Expand Partnership for mRNA Vaccine Ecosystem in Africa	May. 29
Keine Corona-Impfpflicht mehr für Soldaten - Bundesgericht am Zug	May. 29
BioNTech gets $145 mln funding for African vaccine plants	May. 29

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

BIONTECH : A miss is a miss

March 21, 2024 at 09:27 am EDT